Litigation Details for Teva Pharmaceuticals USA Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

« Back to Dashboard

Teva Pharmaceuticals USA Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

Docket		Date Filed	2014-10-06
Court	District Court, D. Delaware	Date Terminated	2017-01-31
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	8,232,250; 8,399,413
Link to Docket	External link to docket

Details for Teva Pharmaceuticals USA Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-10-06				External link to document

Teva Pharmaceuticals USA Inc. v. Mylan Pharmaceuticals Inc. | 1:14-cv-01278 Litigation Summary

Last updated: August 5, 2026

Teva Pharmaceuticals USA Inc. sued Mylan Pharmaceuticals Inc. in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act after Mylan submitted an abbreviated new drug application (ANDA) for a generic version of Copaxone, Teva’s glatiramer acetate injection for multiple sclerosis. The case involved Teva’s later-expiring Copaxone patent estate, including patents directed to glatiramer acetate products and dosing regimens. The dispute was part of Teva’s broader effort to delay generic competition to Copaxone 40 mg/mL.

The litigation did not establish durable market exclusivity for Teva. Mylan ultimately received FDA approval for generic glatiramer acetate and entered the market after the relevant patent disputes and regulatory barriers were resolved. The case is best understood as a product-specific Hatch-Waxman action within the broader Copaxone patent campaign, rather than as a standalone pharmaceutical patent ruling.

What drug and patents were at issue in Teva v. Mylan?

The case concerned glatiramer acetate, marketed by Teva as Copaxone. Copaxone is an injectable immunomodulator approved for relapsing forms of multiple sclerosis.

Product and regulatory profile

Item	Details
Brand	Copaxone
Active ingredient	Glatiramer acetate
Dosage forms	20 mg/mL daily injection; 40 mg/mL injection three times weekly
Reference sponsor	Teva Pharmaceuticals USA Inc.
Regulatory pathway	ANDA under the Hatch-Waxman Act
Defendant	Mylan Pharmaceuticals Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:14-cv-01278
Presiding judge	Judge Richard G. Andrews
Core commercial issue	Mylan’s proposed generic glatiramer acetate product

The asserted Copaxone estate included patents covering glatiramer acetate compositions, pharmaceutical formulations, and methods of administering the product. Publicly litigated Copaxone patents included U.S. Patent Nos. 8,232,250 and 8,399,413, along with later patents addressing dosing and related product characteristics. The precise patents asserted against Mylan must be distinguished from patents asserted in Teva’s parallel cases against Sandoz, Synthon and other ANDA filers.

When did Teva file the case and what triggered the lawsuit?

Teva filed the action in 2014 after receiving Mylan’s Paragraph IV certification. Under the Hatch-Waxman framework, a Paragraph IV certification states that a listed patent is invalid, unenforceable or will not be infringed by the proposed ANDA product. The certification creates a statutory basis for the brand company to sue for patent infringement before generic approval.

The filing triggered the statutory 30-month stay of FDA approval, subject to court rulings and other regulatory events. Teva’s objective was to preserve Copaxone’s market position while litigating the validity and scope of its patents. Mylan’s objective was to obtain approval and launch without waiting for the full expiration of Teva’s listed patents.

What were Teva’s infringement claims against Mylan?

Teva alleged that Mylan’s proposed generic product would infringe Copaxone patents under 35 U.S.C. § 271(e)(2), which treats the filing of an ANDA as an artificial act of infringement for purposes of patent litigation.

The claims fell into three principal categories:

Composition and product claims

These claims covered glatiramer acetate products with specified molecular-weight distributions, chemical characteristics or compositional parameters. The technical difficulty was that glatiramer acetate is a heterogeneous polymer rather than a single molecular entity. Patent scope therefore depended on analytical definitions, product characteristics and the relationship between the claimed composition and the proposed generic product.

Formulation claims

Formulation-related claims addressed injectable pharmaceutical compositions containing glatiramer acetate and excipients. These claims were commercially important because they could remain relevant even after earlier composition patents expired.

Method-of-use and dosing claims

Later Copaxone patents addressed the administration of glatiramer acetate, including the three-times-weekly 40 mg/mL regimen. Method-of-use claims created a potential barrier to generic approval or launch, although they were subject to the limitations of skinny-labeling rules and the requirement that the generic product be approved for non-patented uses.

The scope of Teva’s enforcement strategy was limited by the uncertainty surrounding Copaxone’s complex active ingredient and by the Federal Circuit’s scrutiny of written-description, obviousness and claim-construction theories in related Copaxone appeals. See Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 789 F.3d 1335 (Fed. Cir. 2015).

How did Mylan defend the Copaxone patent claims?

Mylan’s defenses followed the standard ANDA litigation framework:

1. The proposed product did not infringe the asserted claims.
2. The asserted claims were invalid for lack of written description or enablement.
3. The claims were obvious in view of prior art.
4. Teva’s patent rights should not extend beyond the technical disclosure and legally permissible claim scope.
5. Any method-of-use restrictions could be addressed through labeling and the ANDA approval process.

The written-description issue was particularly significant for Copaxone. Because glatiramer acetate is a complex mixture, the question was whether Teva’s patent specifications adequately described the claimed product characteristics and provided possession of the claimed subject matter at the relevant filing date. The Federal Circuit’s related Copaxone decisions narrowed the enforceable value of some Teva patent claims. [1]

What was the court’s procedural history?

The case was filed in the District of Delaware in 2014. It proceeded as a Hatch-Waxman action involving claim construction, patent validity, infringement and the regulatory consequences of Mylan’s ANDA filing.

Litigation timeline

Date	Event
2014	Teva filed Civil Action No. 1:14-cv-01278 against Mylan in Delaware
2014-2015	Mylan litigated Teva’s asserted Copaxone patent rights and challenged infringement and validity
2015	Federal Circuit issued a major related Copaxone decision involving Teva’s patent estate
2016-2017	Regulatory and market access disputes continued across the Copaxone generic field
2017	Mylan obtained FDA approval for generic glatiramer acetate 40 mg/mL and entered the U.S. market

The case should not be analyzed solely through the docket’s initial filing. Copaxone litigation involved multiple defendants, patent families and appeals. A ruling in Teva v. Sandoz did not automatically resolve every issue in Teva v. Mylan, and a settlement or dismissal in one defendant’s case did not necessarily eliminate Teva’s rights against other ANDA sponsors.

What was the outcome of Teva v. Mylan?

The litigation did not prevent Mylan from ultimately entering the generic glatiramer acetate market. Mylan launched generic glatiramer acetate 40 mg/mL in 2017 after FDA approval. The commercial result indicates that Teva did not obtain a litigation outcome capable of blocking Mylan through the full remaining life of the relevant Copaxone estate.

The case’s practical outcome was therefore a negotiated or otherwise resolved pathway to generic entry rather than a permanent injunction against Mylan. Publicly reported market events show that Mylan became a commercial supplier of generic glatiramer acetate, while Teva continued to market Copaxone and compete through pricing, formulation differentiation and product positioning. [2]

What was the Orange Book status of Copaxone?

Copaxone’s Orange Book position changed over time as patents expired, were delisted, were challenged or became commercially less effective.

Orange Book and exclusivity considerations

Copaxone’s earliest patent protection did not provide indefinite protection against generic competition. Teva relied on later patents to extend its enforcement position, particularly around the 40 mg/mL three-times-weekly regimen and product characteristics.

The most important regulatory distinction was between:

• patents listed for the reference product;
• patents that could support a Paragraph IV suit;
• method-of-use patents that could be addressed through labeling; and
• patents whose remaining term had limited commercial value because of validity or infringement risk.

FDA approval of Mylan’s generic product demonstrates that the regulatory process ultimately accommodated a generic product despite Teva’s patent portfolio. FDA’s approval of generic glatiramer acetate products also reflected the agency’s product-specific approach to demonstrating pharmaceutical equivalence and therapeutic equivalence for this complex synthetic polymer. [3]

When did Copaxone lose exclusivity and when did generic entry occur?

Copaxone did not lose all protection on a single date. Exclusivity eroded in stages.

The 20 mg/mL daily product faced earlier generic pressure than the 40 mg/mL three-times-weekly product. Teva’s later patents attempted to maintain protection for the higher-strength regimen and related product characteristics. Generic competition became commercially meaningful in 2017, when FDA approved products from Mylan and other sponsors.

Generic entry scenario

Scenario	Commercial effect
No successful Paragraph IV challenge	Generic approval delayed by patent litigation and the statutory stay
Settlement with an agreed launch date	Generic entry before full patent expiry, subject to settlement terms
Invalidity or non-infringement judgment	Immediate or accelerated generic entry, subject to FDA approval
Skinny-label approval	Generic may enter for non-patented indications while omitting protected use
Multiple approved generics	Rapid price erosion and increased payer substitution

Mylan’s 2017 entry materially weakened Teva’s ability to preserve Copaxone pricing through patent enforcement alone. Teva’s subsequent commercial response included price reductions and efforts to retain patients through product and service differentiation. [2]

Which companies challenged Teva’s Copaxone patents?

Teva faced challenges from several generic and specialty pharmaceutical companies, including Mylan and Sandoz. The Copaxone patent campaign also involved other ANDA applicants seeking approval for glatiramer acetate products.

The competitive landscape had four relevant groups:

1. Teva, as reference sponsor and patent holder.
2. Mylan, as an ANDA applicant and eventual generic entrant.
3. Sandoz, which litigated major Copaxone patent issues and launched a generic product.
4. Other generic manufacturers seeking approval after the first entrants reduced regulatory and technical uncertainty.

The first commercially significant generic entrants had a stronger position than later entrants because they could obtain market share before prices declined and before payers completed broad substitution programs.

How strong was Teva’s Copaxone patent estate?

Teva’s Copaxone estate was broad but uneven.

Strengths

• Large commercial product with substantial revenue exposure.
• Multiple patent families covering different aspects of the product.
• Ability to assert product, formulation and method-of-use claims.
• Complex active ingredient that created technical barriers for generic development.
• Hatch-Waxman litigation that delayed approval during the statutory stay.

Weaknesses

• Glatiramer acetate’s heterogeneous structure complicated claim scope.
• Written-description and enablement theories created validity risk.
• Some patents were vulnerable to claim-construction disputes.
• Method-of-use claims had limited value where a generic could use a permissible label.
• Multiple generic applicants increased the probability of eventual entry.
• Related Federal Circuit rulings reduced confidence in the enforceability of certain claims.

The estate was commercially valuable but litigation-sensitive. Its practical strength depended less on the number of issued patents than on whether a particular claim could survive validity review and cover the precise ANDA product.

What patent litigation affected Teva’s Copaxone revenue?

Copaxone was one of Teva’s most important products before generic competition. Teva reported that U.S. generic entry caused substantial pressure on Copaxone sales, pricing and market share. The company’s annual reports identified generic competition and patent litigation as material risks to the product’s revenue base. [2]

The revenue exposure had three dimensions:

• direct price erosion from generic substitution;
• loss of volume as patients moved to generic glatiramer acetate;
• reduced ability to preserve a premium for Copaxone through brand loyalty alone.

Mylan’s entry also affected the value of licensing and settlement negotiations. A settlement that delayed entry could preserve substantial revenue, while a launch-at-risk strategy could expose the generic manufacturer to damages if the patents were later upheld.

Did Teva and Mylan enter a settlement agreement?

The public record for the specific civil action must be separated from broader Copaxone settlements involving other defendants. Hatch-Waxman cases often terminate through dismissal after the parties agree on an authorized or licensed launch date, but the docket disposition alone does not establish the full commercial terms of a confidential agreement.

The commercially observable result is that Mylan entered the U.S. glatiramer acetate market in 2017. Any settlement analysis should therefore focus on:

• the agreed launch date;
• whether Mylan received an authorized-generic right;
• whether Teva supplied product or granted a license;
• the treatment of later patents;
• whether the agreement included a no-challenge provision;
• the agreement’s antitrust and FTC reporting implications.

Confidential settlement terms should not be inferred from the fact of dismissal or from Mylan’s eventual product launch.

What generic entry risks existed for Mylan?

Mylan faced several risks before launch:

• patent infringement damages if it launched before the asserted patents were resolved;
• an injunction if Teva obtained relief;
• technical failure in demonstrating equivalence for glatiramer acetate;
• manufacturing and analytical challenges associated with a complex polymer;
• market-share erosion from competing generic entrants;
• payer resistance if Copaxone retained favorable formulary placement.

Mylan’s eventual FDA approval and launch show that the company overcame the primary regulatory and technical barriers. The commercial risk then shifted from patent clearance to price competition and product substitution.

What does the case mean for pharmaceutical patent strategy?

Teva v. Mylan illustrates the limits of lifecycle patenting for complex injectable products. A sponsor may obtain multiple patents after the original composition patent, but each later patent must independently survive validity and infringement scrutiny.

For complex synthetic polymers, patent value depends on:

• reproducible analytical characterization;
• disclosure of representative compositions;
• clear linkage between the claimed characteristics and the commercial product;
• defensible distinctions from prior art;
• method-of-use claims that cannot be bypassed through labeling.

For generic companies, the case supports early Paragraph IV challenges where the patent estate has claim-construction or written-description weaknesses. It also shows that regulatory approval and commercial launch can occur even when a brand sponsor maintains a substantial number of listed patents.

Key Takeaways

• Teva v. Mylan, No. 1:14-cv-01278, was a Delaware Hatch-Waxman case involving Mylan’s ANDA for generic Copaxone.
• The active ingredient was glatiramer acetate, used to treat relapsing multiple sclerosis.
• Teva asserted later Copaxone patents covering product characteristics, formulations and dosing.
• Mylan challenged infringement and patent validity through Paragraph IV litigation.
• Related Federal Circuit decisions exposed weaknesses in portions of Teva’s Copaxone patent estate.
• Mylan received FDA approval and entered the U.S. market with generic glatiramer acetate 40 mg/mL in 2017.
• The case did not produce a durable injunction blocking Mylan’s generic product.
• The main commercial consequence was erosion of Teva’s Copaxone revenue and pricing power.
• The dispute demonstrates that patent count is a poor substitute for claim-specific validity and infringement analysis.

FAQs About Teva v. Mylan and Copaxone Patent Litigation

Was Teva v. Mylan a biologic or biosimilar case?

No. Copaxone is a complex synthetic polymer drug, not a biologic subject to the Biologics Price Competition and Innovation Act biosimilar pathway. Mylan pursued an ANDA-based generic approval.

Did Mylan launch generic Copaxone before all Teva patents expired?

Mylan entered after FDA approval and resolution of the relevant regulatory and litigation barriers. Generic entry occurred before the complete expiration of every patent associated with Teva’s broader Copaxone portfolio.

What was the most important technical issue in the Copaxone cases?

The key technical issue was how to define and claim a heterogeneous glatiramer acetate polymer with sufficient written-description support and reliable analytical boundaries.

Did Teva’s Copaxone patents cover only the active ingredient?

No. The estate included patents directed to product characteristics, pharmaceutical compositions and methods of administering glatiramer acetate.

Did Mylan’s entry eliminate Copaxone from the market?

No. Teva continued to sell Copaxone after generic entry, but faced lower prices, reduced market share and increased payer substitution.

References

1. Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 789 F.3d 1335 (Fed. Cir. 2015).

2. Teva Pharmaceutical Industries Ltd. Annual Report (Form 20-F) (2017-2019), disclosures concerning Copaxone sales, generic competition and patent litigation.

3. U.S. Food and Drug Administration. (2017). FDA approves first generic versions of Copaxone. FDA Drug Safety and Availability Communications.